Coagulation in brain tumors: biological and clinical aspects
- 1Istituto Nazionale del Cancro Regina Elena, Italy
- 2Bambino Gesù Children Hospital (IRCCS), Italy
Cancer patients commonly show abnormal laboratory coagulation tests, indicating a subclinical hypercoagulable condition that contribute to morbidity and mortality. The hypercoagulation status not only increases the risk of thromboembolic events but also influences the tumor biology promoting its growth and progression by stimulating intracellular signaling pathways. Recent molecular studies characterized the role of oncogene and repressor gene in activating clotting pathways, as an integral feature of the neoplastic transformation. It is now clear how haemostatic processes, activated by cancer cells harboring oncogenic mutations, rely on the molecular profile of a particular malignancy, an aspect particularly evident in the differential coagulome profiles showed by different molecular subtypes of brain tumors, such as glioblastoma and medulloblastoma.
This review focuses on the biological and clinical aspects of haemostasis in cancer with particular regard on brain tumors.
Keywords: Thromboembolism, Glioblastoma, tissue factor, Oncogenes, TF Microparticles
Received: 14 Dec 2018;
Accepted: 13 Feb 2019.
Edited by:Sandro M. Krieg, MD, MBA, Technische Universität München, Germany
Reviewed by:Janusz Rak, McGill University, Canada
Ulises Gomez-Pinedo, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Spain
Vance G. Nielsen, Department of Anesthesiology, University of Arizona
Copyright: © 2019 Mandoj, Tomao and Conti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: MD, PhD. Laura Conti, Istituto Nazionale del Cancro Regina Elena, Rome, 00144, Lazio, Italy, email@example.com